Agilent Technologies (NYSE:A) Releases Q2 2026 Earnings Guidance

Agilent Technologies (NYSE:A) updated its second quarter 2026 earnings guidance on Wednesday. The company provided EPS guidance of 1.390-1.420 for the period, compared to the consensus EPS estimate of 1.400. The company issued revenue guidance of $1.8 billion-$1.8 billion, compared to the consensus revenue estimate of $1.8 billion. Agilent Technologies also updated its FY 2026 guidance to 5.900-6.040 EPS.

Agilent Technologies Price Performance

Shares of NYSE:A traded down $9.15 during trading on Thursday, reaching $115.57. The company had a trading volume of 2,158,816 shares, compared to its average volume of 2,094,009. The firm’s fifty day moving average is $135.31 and its 200 day moving average is $135.97. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96. The firm has a market capitalization of $32.69 billion, a PE ratio of 25.27, a price-to-earnings-growth ratio of 3.61 and a beta of 1.30. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $160.27.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing the consensus estimate of $1.37 by ($0.01). The firm had revenue of $1.80 billion for the quarter, compared to the consensus estimate of $1.81 billion. Agilent Technologies had a return on equity of 25.20% and a net margin of 18.75%.Agilent Technologies’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, equities analysts forecast that Agilent Technologies will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Investors of record on Tuesday, March 31st will be issued a dividend of $0.255 per share. This represents a $1.02 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, March 31st. Agilent Technologies’s payout ratio is presently 22.32%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on A shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Agilent Technologies in a report on Monday, December 29th. Morgan Stanley assumed coverage on shares of Agilent Technologies in a report on Tuesday, December 2nd. They issued an “overweight” rating on the stock. The Goldman Sachs Group started coverage on shares of Agilent Technologies in a research note on Tuesday, December 9th. They set a “buy” rating and a $170.00 target price for the company. HSBC started coverage on shares of Agilent Technologies in a research report on Tuesday, January 20th. They issued a “buy” rating and a $180.00 price target on the stock. Finally, Robert W. Baird increased their price objective on Agilent Technologies from $142.00 to $165.00 and gave the company an “outperform” rating in a research report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $162.71.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Management set FY‑2026 revenue of $7.3B–$7.5B and expanded its “Ignite” operating‑system effort aimed at margin improvement — a constructive forward signal that supports medium‑term profit growth. Read More.
• Positive Sentiment: Wall Street remains broadly supportive: the recent analyst coverage shows many buy/overweight ratings and a median price target near $170, leaving upside at current levels if execution continues. Read More.
• Neutral Sentiment: Agilent described Q1 results as largely in‑line with Street expectations and blamed U.S. snowstorms for some top‑line disruption — this helps explain the small miss but leaves mixed signals for investors. Read More.
• Neutral Sentiment: Company Q1 disclosures and the slide deck/earnings call are available for investors who want to assess guidance detail and segment trends before betting on a rebound. Read More.
• Negative Sentiment: Q1 EPS missed by $0.01 and revenue came in slightly below estimates ($1.80B vs. ~$1.81B), which triggered near‑term selling pressure as algos and traders react to the headline misses. Read More.
• Negative Sentiment: Operating cash flow and operating profit showed weakness in the quarter (cash from ops down meaningfully year‑over‑year), a red flag for investors focused on free cash generation and buyback/dividend capacity. Read More.
• Negative Sentiment: Analysts at Wells Fargo and Barclays cut price targets (Wells Fargo $175→$165; Barclays $165→$150) — still overweight, but the trims remove some near‑term bullish momentum and likely contributed to the stock pullback. Read More. Read More.
• Negative Sentiment: Notable insider sales and large institutional portfolio reductions were flagged in the quarter, which can exacerbate selling pressure or signal cautious positioning by some large holders. Read More.

Institutional Trading of Agilent Technologies

Hedge funds have recently made changes to their positions in the stock. State Street Corp raised its position in shares of Agilent Technologies by 1.9% in the fourth quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after purchasing an additional 241,029 shares during the period. Morgan Stanley increased its stake in Agilent Technologies by 15.9% during the fourth quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock valued at $686,049,000 after acquiring an additional 692,202 shares during the period. Invesco Ltd. raised its stake in shares of Agilent Technologies by 32.0% in the fourth quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock valued at $352,519,000 after purchasing an additional 627,804 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Agilent Technologies by 132.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after buying an additional 1,340,161 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Agilent Technologies by 424.1% during the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after purchasing an additional 1,652,244 shares in the last quarter.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.